Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to $604000.0.

  • Oncology Institute's Capital Expenditures rose 25024.88% to $604000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 3454.23%. This contributed to the annual value of $3.8 million for FY2024, which is 1703.53% down from last year.
  • Latest data reveals that Oncology Institute reported Capital Expenditures of $604000.0 as of Q3 2025, which was up 25024.88% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Capital Expenditures ranged from a high of $2.0 million in Q4 2022 and a low of -$402000.0 during Q3 2024
  • Over the past 5 years, Oncology Institute's median Capital Expenditures value was $937000.0 (recorded in 2023), while the average stood at $993263.2.
  • As far as peak fluctuations go, Oncology Institute's Capital Expenditures tumbled by 14322.58% in 2024, and later skyrocketed by 25024.88% in 2025.
  • Oncology Institute's Capital Expenditures (Quarter) stood at $871000.0 in 2021, then surged by 129.05% to $2.0 million in 2022, then crashed by 56.84% to $861000.0 in 2023, then soared by 103.83% to $1.8 million in 2024, then crashed by 65.58% to $604000.0 in 2025.
  • Its last three reported values are $604000.0 in Q3 2025, $1.2 million for Q2 2025, and $328000.0 during Q1 2025.